These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38616113)

  • 1. LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice.
    Munkhjargal U; Fukuda D; Maeda J; Hara T; Okamoto S; Bavuu O; Yamamoto T; Sata M
    J Atheroscler Thromb; 2024 Sep; 31(9):1333-1340. PubMed ID: 38616113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
    Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
    Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
    Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
    Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
    Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
    [No Abstract]   [Full Text] [Related]  

  • 6. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
    Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
    Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome.
    Li Y; Kang L; Rong K; Zhang Y; Suo Y; Yuan M; Bao Q; Shao S; Tse G; Li R; Liu T; Li G
    Life Sci; 2021 Sep; 280():119692. PubMed ID: 34102189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice.
    Munkhjargal U; Fukuda D; Ganbaatar B; Suto K; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Yagi S; Yamada H; Soeki T; Wakatsuki T; Sata M
    J Atheroscler Thromb; 2023 Apr; 30(4):326-334. PubMed ID: 35732424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates epithelial-mesenchymal transition of peritoneal mesothelial cells and M2 macrophage polarization.
    Hu Y; Zhou C; Zhong Q; Li X; Li J; Shi Y; Ma X; Jiang D; Wang Y; Zhuang S; Liu N
    Ren Fail; 2024 Dec; 46(2):2392849. PubMed ID: 39165231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
    J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
    Bai HY; Mogi M; Nakaoka H; Kan-No H; Tsukuda K; Chisaka T; Wang XL; Kukida M; Shan BS; Yamauchi T; Higaki A; Iwanami J; Horiuchi M
    Eur J Pharmacol; 2015 Sep; 762():293-8. PubMed ID: 26057694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.
    Esser N; Schmidt C; Barrow BM; Cronic L; Hackney DJ; Mongovin SM; Hogan MF; Templin AT; Castillo JJ; Hull RL; Zraika S
    Front Endocrinol (Lausanne); 2022; 13():888867. PubMed ID: 35733766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
    Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
    Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
    Kobalava Z; Kotovskaya Y; Averkov O; Pavlikova E; Moiseev V; Albrecht D; Chandra P; Ayalasomayajula S; Prescott MF; Pal P; Langenickel TH; Jordaan P; Rajman I
    Cardiovasc Ther; 2016 Aug; 34(4):191-8. PubMed ID: 26990595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
    Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
    Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
    Ayalasomayajula S; Langenickel TH; Chandra P; Wolfson ED; Albrecht D; Zhou W; Pal P; Rajman I; Sunkara G
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1012-1018. PubMed ID: 27719743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
    Zhang H; Liu G; Zhou W; Zhang W; Wang K; Zhang J
    Sci Rep; 2019 Apr; 9(1):6509. PubMed ID: 31019233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.